
Release date: 2025-03-10 13:24:29 Article From: Lucius Laos Recommended: 243
The choice and use of drugs is crucial on the road to cancer treatment. A proper understanding of the properties and precautions of the drug can help patients better manage their health.
As a targeted therapy for lung cancer targeting specific gene mutations, osimertinib needs to pay special attention to some key points in practical application.
Each patient's constitution and condition are different, so it is important to perform detailed genetic testing to confirm the presence of the corresponding EGFR mutation before starting osimertinib therapy. This step is essential to determine whether the drug is appropriate for use.
Pay close attention to possible side effects, such as diarrhea and rashes. These symptoms are usually mild and manageable, but if you experience severe discomfort, you should talk to your health care team about adjusting your dose or taking other measures.
Because tumors may develop resistance to osimertinib, regular follow-up and efficacy assessments are essential. By continuously monitoring the disease status, the treatment plan can be adjusted in time to improve the treatment effect.
With the advancement of science, new hopes are emerging in the field of cancer treatment.
In recent years, immune checkpoint inhibitors have become a major breakthrough in cancer treatment, as they activate the body's own immune system to fight cancer cells. This approach opens up new options for patients who are not candidates for traditional chemotherapy or targeted therapy.
Combining different treatments, such as targeted therapy with immunotherapy, can sometimes have a synergistic effect and increase treatment success. This multimodal approach is being widely studied and practiced.
In addition to directly fighting the tumor, providing good supportive care is also part of the treatment plan. This includes nutritional support, psychological counseling, etc., which can help improve the quality of life of patients.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643